No. Lack of double-blinding will increase the false negative rate too, if the patients, doctors or examiners think that something shouldn't work or should be actively harmful. If you test a bunch of people who believe that aspartame gives them headaches or that wifi gives them nausea without blinding them you'll get garbage out as surely as if you test homeopathic remedies unblinded on a bunch of people who think homeopathic remedies cure all ills.
In this particular case I think it's likely the system worked because it's relatively hard to kid yourself about progressing ALS symptoms, and even with a hole in the blinding sometimes more data is just better. This is about as easy as medical problems get.
Generalising from this to the management of chronic problems seems like a major mistake. There's far, far more scope to fool oneself with placebo effects, wishful thinking, failure to compensate for regression to the mean, attachment to a hypothesis and other cognitive errors with a chronic problem.
Fair enough. I don't think the biases are symmetrical though: these people have a real and life-threatening disease, so they approach any intervention hoping strongly that it will work; hence we should expect them to yield more false positives than false negatives compared to whatever an equal medical trial would yield. On the other hand, when we're looking at the chatrooms of hypochondriacs & aspartame sufferers, I think we can expect the bias to be reversed: if even crazy people find nothing to take offense to in something, that something may well be...
When you're suffering from a life-changing illness, where do you find information about its likely progression? How do you decide among treatment options?
You don't want to rely on studies in medical journals because their conclusion-drawing methodologies are haphazard. You'll be better off getting your prognosis and treatment decisions from a social networking site: PatientsLikeMe.com.
PatientsLikeMe.com lets patients with similar illnesses compare symptoms, treatments and outcomes. As Jamie Heywood at TEDMED 2009 explains, this represents an enormous leap forward in the scope and methodology of clinical trials. I highly recommend his excellent talk, and I will paraphrase part of it below.